Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of hATG, Cyclosporine, Methylprednisolone, and GCSF in AA or MDS
NCT01624805Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2012
- Primary completion
- Jun 2029
- Modality
- Orthosteric Ligands, Cytokines & Interferons, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of antithymocyte globulin rabbit, cyclosporine, filgrastim, methylprednisolone injection, pegfilgrastim in aplastic anemia, myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2012; status: recruiting.
02
Drugs
antithymocyte globulin rabbitcyclosporinefilgrastimmethylprednisolone injectionpegfilgrastim
03
Conditions
aplastic anemiamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01624805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01624805.